Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.

ABSTRACT:

Background

Sarcomas constitute a heterogeneous group of tumors with different clinical behaviors and variable responses to systemic therapies. Recent immunotherapy studies with PD1 inhibitors (PD1i) show promising results with use in certain soft-tissue sarcomas; however, the clinical and molecular features that best predict response to PD1i remain unclear.

Methods

Demographic, imaging, histologic, and genetic sequencing data was collected for sarcoma patients who received nivolumab or pembrolizumab (PD1i) treatment at our institution between January 1st 2015 and April 23rd 2018. The primary objective was to determine progression-free survival (PFS) in patients with advanced sarcomas receiving PD1i. Secondary objectives included determining overall survival (OS) and assessme

SUBMITTER: Quiroga D 

PROVIDER: S-EPMC7275332 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature